BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25144562)

  • 41. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The diagnostic value of (18)F-FDG PET-CT imaging in patients with primary extranodal lymphoma].
    Dang N; Xu W; Song X; Dai D; Zhu L; Zhu X; Ma W; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):35-9. PubMed ID: 24602729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
    Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
    Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
    Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
    Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usefulness of fluorodeoxyglucose positron emission tomography in malignancy of pulmonary artery mimicking pulmonary embolism.
    Lee EJ; Moon SH; Choi JY; Lee KS; Choi YS; Choe YS; Lee KH; Kim BT
    ANZ J Surg; 2013 May; 83(5):342-7. PubMed ID: 22943630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis.
    Salm LP; Van der Hiel B; Stokkel MP
    Nucl Med Commun; 2012 Sep; 33(9):907-16. PubMed ID: 22714006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
    Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
    J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.
    Sobic-Saranovic D; Grozdic I; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko V; Saranovic D; Djuric-Stefanovic A; Masulovic D; Odalovic S; Ilic-Dudvarski A; Popevic S; Pavlovic S; Obradovic V
    J Nucl Med; 2012 Oct; 53(10):1543-9. PubMed ID: 22879080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.